SRTD Biotech has raised €31.5M in Seed funding, led by Mérieux Equity Partners. The funds will be used to advance preclinical development of their mRNA therapeutics targeting oncology, autoimmune, and fibrosis indications.
Amount Raised
€31.5 Million
Round Type
Seed
DürenBiotechnologyHealth CareTherapeuticsInvestors
Description
SRTD Biotech, based in Jülich, Germany, focused on developing precision mRNA therapeutics, has raised €31.5M in Seed funding. The round was led by Mérieux Equity Partners, with NRW.BANK and Boehringer Ingelheim Venture Fund as co-leads. Additionally, Lilly Ventures, HTGF, and Anobis Asset participated. The funds will support the preclinical development of their novel targeted RNA therapies.
Quick answer
SRTD biotech raised €31.5 Million in a Seed round, dated November 9, 2026. Investors: Anobis Asset, Htgf, Lilly Ventures, Boehringer Ingelheim Venture Fund, Nrw.Bank and Mérieux Equity Partners. SRTD biotech is based in Düren, North Rhine-Westphalia, Germany.
- How much did SRTD biotech raise?
- SRTD biotech raised €31.5 Million in a Seed round on November 9, 2026.
- Who invested in SRTD biotech?
- Anobis Asset, Htgf, Lilly Ventures, Boehringer Ingelheim Venture Fund, Nrw.Bank and Mérieux Equity Partners are named as investors in this round.
- What does SRTD biotech do?
- SRTD biotech is a company based in Jülich, Germany, specializing in RNA-based therapeutics.
- Where is SRTD biotech based and how big is it?
- SRTD biotech is based in Düren, North Rhine-Westphalia, Germany. Fundz records about 13 employees.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as SRTD biotech that raised within 45 days of this round, from Fundz verified event records.
- Lifeplex Science raised $5.3M (Series A) on November 13, 2026.
- Orakl Oncology raised $34M (Series A) on November 12, 2026.
- Neurosterix raised $105M (Series B) on November 11, 2026.
- VectorY raised $83M on November 11, 2026.
- Oyster Therapeutics raised $60M (Series A) on November 10, 2026.
- BioVie raised $4.7M (Post-IPO Equity) on November 6, 2026.
Who to call at SRTD biotech, and when
A new round usually means SRTD biotech is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day SRTD biotech raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at SRTD biotech, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at SRTD biotech. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment SRTD biotech raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
SRTD biotech raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.